News

Learn how and why East Indian Sandalwood Oil (EISO) is making international headlines as a unique, non-substitutable botanical drug candidate.

News

San Antonio Biotech Company Viroxis Clears a Big Regulatory Hurdle

Posted on

Friday, April 8, 2011 San Antonio based Viroxis Corp. has cleared one of the biggest hurdles in its bid to take its new anti-wart drug compound to market. The U.S. Food and Drug Administration has approved Viroxis’ application for Phase II clinical testing to treat patients with its new compound — a substance derived from East Indian Sandalwood oil for […]Read More San Antonio Biotech Company Viroxis Clears a Big Regulatory Hurdle

ViroXis Corporation Initiates Phase II Clinical Trial of Novel Botanical Topical Treatment for HPV Skin Warts

Posted on

April 08, 2011 08:00 AM Eastern Daylight Time SAN ANTONIO–(MEDIA)–ViroXis Corporation today announced that the US Food and Drug Administration (FDA) granted approval for the Company’s investigational new drug (IND) application and planned clinical development of a drug substance derived from East Indian Sandalwood oil (EISO) for the topical treatment of Human Papilloma Virus (HPV), common warts of the skin. […]Read More ViroXis Corporation Initiates Phase II Clinical Trial of Novel Botanical Topical Treatment for HPV Skin Warts

Grants Awarded to 16 S.A. Biotech Companies

Posted on

Federal tax-credit grants totaling about $4.9 million have been awarded to 16 San Antonio biotechnology companies. The grants are among $1 billion that was made available under the health care reform legislation signed into law in March. Most of the San Antonio companies received grants worth $244,479, though six companies each received two grants of varying amounts. The companies are […]Read More Grants Awarded to 16 S.A. Biotech Companies